BioNTech shares fall 5% after BNT113 clinical trial fails to meet primary endpoint
BNTX BioNTech SE ADR
$95.84 -1.16%
View chart & analysis → - 1BioNTech reported that the BNT113 clinical trial did not meet its initial primary endpoint.
- 2BioNTech shares fell 5% on Tuesday.
- 3The independent data monitoring committee recommended continuing the study to evaluate the other primary endpoint, overall survival.
So what's the key point?
The drug trial being conducted by BioNTech did not achieve its initial target results. Shares fell 5% following this news.
Source InvestorsHub +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.